Literature DB >> 25006408

Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure.

Gustavo A Heresi1, Omar A Minai1, Adriano R Tonelli1, Jeffrey P Hammel1, Samar Farha1, Joseph G Parambil1, Raed A Dweik2.   

Abstract

Normal resting mean pulmonary artery pressure (PAP) is 8-20 mmHg. Pulmonary hypertension is defined as mean PAP of ≥25 mmHg. Borderline PAP levels of 21-24 mmHg are of unclear significance. We sought to determine the clinical characteristics and survival of subjects with mean PAP of 21-24 mmHg. We examined 1,491 patients enrolled in the Cleveland Clinic Pulmonary Hypertension Registry between February 1990 and May 2012 with baseline right heart catheterization. The relationship between PAP and all-cause mortality was assessed by Cox models and a tree-based analysis. Sixty-three patients had borderline PAP (underlying conditions: 12 left heart disease, 20 respiratory disease, 17 connective-tissue disease, 4 others, and 10 none). We then compared 3 groups: borderline PAP without heart or lung disease ([Formula: see text]), normal PAP without heart or lung disease ([Formula: see text]), and category 1 pulmonary arterial hypertension (PAH; [Formula: see text]). Borderline-PAP patients had levels of hemodynamic and functional compromise between those for normal-PAP patients and those for patients with PAH. Borderline PAP was associated with increased mortality compared to normal PAP (hazard ratio: 4.03 [95% confidence interval: 0.78-20.80], [Formula: see text]). A tree-based analysis demonstrated almost identical cut points in mean PAP (≤20, 21-26, and ≥27 mmHg) associated with differential survival ([Formula: see text]). Connective-tissue disease and an elevated transpulmonary gradient were predictors of worse survival in the borderline-PAP population. Borderline PAP elevation is associated with decreased survival, particularly in the context of connective-tissue disease and an elevated transpulmonary gradient.

Entities:  

Keywords:  pulmonary artery pressure; pulmonary heart disease; pulmonary hypertension; survival

Year:  2013        PMID: 25006408      PMCID: PMC4070822          DOI: 10.1086/674756

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  20 in total

1.  Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed.

Authors:  N Galiè; M Palazzini; A Manes
Journal:  Eur Respir J       Date:  2010-11       Impact factor: 16.671

2.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

Review 4.  Diagnosis and assessment of pulmonary arterial hypertension.

Authors:  David B Badesch; Hunter C Champion; Miguel Angel Gomez Sanchez; Marius M Hoeper; James E Loyd; Alessandra Manes; Michael McGoon; Robert Naeije; Horst Olschewski; Ronald J Oudiz; Adam Torbicki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  Sleep quality, depression, and quality of life in patients with pulmonary hypertension.

Authors:  Omar Batal; Omar F Khatib; Nancy Bair; Loutfi S Aboussouan; Omar A Minai
Journal:  Lung       Date:  2010-12-21       Impact factor: 2.584

6.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

7.  Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis.

Authors:  Kunio Hamada; Sonoko Nagai; Shigeru Tanaka; Tomohiro Handa; Michio Shigematsu; Taishi Nagao; Michiaki Mishima; Masanori Kitaichi; Takateru Izumi
Journal:  Chest       Date:  2007-02-22       Impact factor: 9.410

8.  Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients.

Authors:  A Chaouat; E Weitzenblum; J Krieger; M Oswald; R Kessler
Journal:  Chest       Date:  1996-02       Impact factor: 9.410

9.  Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma.

Authors:  Gabor Kovacs; Robert Maier; Elisabeth Aberer; Marianne Brodmann; Stefan Scheidl; Natascha Tröster; Christian Hesse; Wolfgang Salmhofer; Winfried Graninger; Ekkehard Gruenig; Lewis J Rubin; Horst Olschewski
Journal:  Am J Respir Crit Care Med       Date:  2009-08-13       Impact factor: 21.405

10.  Hemodynamic characterization of patients with severe emphysema.

Authors:  Steven M Scharf; Mobeen Iqbal; Cesar Keller; Gerald Criner; Shing Lee; Henry E Fessler
Journal:  Am J Respir Crit Care Med       Date:  2002-08-01       Impact factor: 21.405

View more
  19 in total

Review 1.  Definition, epidemiology and registries of pulmonary hypertension.

Authors:  R Awdish; H Cajigas
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease.

Authors:  Kim-Lien Nguyen; Xin Tian; Shoaib Alam; Alem Mehari; Steve W Leung; Catherine Seamon; Darlene Allen; Caterina P Minniti; Vandana Sachdev; Andrew E Arai; Gregory J Kato
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

Review 3.  Biomarkers and prognostic indicators in pulmonary arterial hypertension.

Authors:  Carlos Jardim; Rogerio Souza
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 4.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

5.  Early Pulmonary Vascular Disease in Young Adults Born Preterm.

Authors:  Kara N Goss; Arij G Beshish; Gregory P Barton; Kristin Haraldsdottir; Taylor S Levin; Laura H Tetri; Therese J Battiola; Ashley M Mulchrone; David F Pegelow; Mari Palta; Luke J Lamers; Andrew M Watson; Naomi C Chesler; Marlowe W Eldridge
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

6.  Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Authors:  Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary
Journal:  Circulation       Date:  2016-02-12       Impact factor: 29.690

Review 7.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

8.  Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis.

Authors:  Dhaval Kolte; Suvasini Lakshmanan; Matthew D Jankowich; Evan L Brittain; Bradley A Maron; Gaurav Choudhary
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

9.  Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.

Authors:  Bradley A Maron; Nazzareno Galiè
Journal:  JAMA Cardiol       Date:  2016-12-01       Impact factor: 14.676

10.  Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.

Authors:  Tufik R Assad; Bradley A Maron; Ivan M Robbins; Meng Xu; Shi Huang; Frank E Harrell; Eric H Farber-Eger; Quinn S Wells; Gaurav Choudhary; Anna R Hemnes; Evan L Brittain
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.